A trial looking at treatment for cytomegalovirus after stem cell or bone marrow transplant (CMV IMPACT)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Blood cancers
Non-Hodgkin lymphoma




Phase 3

This trial is looking at a new treatment called adoptive cellular therapy (ACT) to treat cytomegalovirus (CMV) after a stem cell or bone marrow transplant.

Following a stem cell or bone marrow transplant the system in the body that fights infection (immune system) may not work properly for several months. During this time serious infections may occur that a healthy body is able to control. The most common infection following a transplant is cytomegalovirus.

Cytomegalovirus (CMV) is common and can cause several types of infections. Most people will have had a CMV infection by the time they are adults. It isn’t generally serious. But the virus can remain inactive in the body for many years and cause recurrent infections. This usually only becomes a problem in people who have a very weakened immune systems. For example, it can cause serious chest infections after a stem cell or bone marrow transplant.

If CMV becomes active again following a transplant doctors usually treat it with drugs. Researchers have developed a new way of treating CMV following a transplant. It is called adoptive cellular therapy – ACT. ACT is a way of boosting the immune cells that fight CMV infection.

Laboratory studies Open a glossary item show that ACT can help control CMV after a transplant. The researchers want to find out if ACT can help boost the immune system of people following a stem cell or bone marrow transplant.

There are 2 main ways to boost the immune cells and the researchers want to compare them to see which the best is.

The aims of this trial are to find out

  • If ACT can help boost the immune system against CMV following a stem cell or bone marrow transplant
  • Which is the best way to boost the immune cells for ACT

Who can enter

You can enter this trial if you

  • Are going to have a stem cell or bone marrow transplant and your brother or sister is the donor
  • Are CMV positive
  • Have alemtuzumab before your transfusion
  • Have satisfactory blood test results
  • At least 18 years old

You cannot enter this trial if you

  • Are HIV positive
  • Have a medical condition that could affect you taking part in this trial
  • Are pregnant or breastfeeding

The researchers would also like to ask your brother or sister to take part in this trial in order to donate cells for ACT. To take part they must be

  • Well enough to be a donor
  • CMV positive
  • At least 16 years old

They cannot enter the trial if they

  • Have tested positive for syphilis, HIV, hepatitis B or C
  • Are pregnant or breastfeeding

Trial design

This is a phase 3 trial. This trial will recruit 95 people who are to have a transplant. The trial will also recruit the brother or sister who is the donor.

It is a randomised trial. There are 2 groups. People in group 1 will have adoptive cellular therapy - ACT. People in group 2 will have standard treatment only for CMV.  Three out of every five people will be put into group 1.  So you have a 3 out of 5 chance of having the experimental treatment in this trial.

ACT is like a second transplant with a certain type of cell. The researchers select the immune cells of your donor with the ability to fight CMV infection. You then have these immune cells that fight CMV through a drip into a vein, like a transfusion. 

Everyone will have a physical examination and blood tests 25 days after their transplant.

If you are in the group having ACT, you have it 2 days later.

If you agree to take part in this trial the researchers will ask your permission to store some of the samples they take. The researchers may use these in the future for further research. You can choose not to have your samples stored and still take part in the trial.

Hospital visits

After your transplant you see the doctor for a physical examination and blood tests

  • Every week for 4 weeks
  • Every month for 7 months

If you are not in hospital, you attend the outpatient’s department to see the doctor.

If you take part in the trial there are no additional visits as these will be the same as the routine visits after your transplant.

Your brother or sister will need to visit the hospital about 17 days after donating their stem cells or bone marrow. This is to donate the blood cells the researchers use for ACT.

Side effects

The side effects of ACT could include

You can find more information about stem cell and bone marrow transplants on CancerHelp UK.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Karl Peggs

Supported by

Cell Medica Limited
Experimental Cancer Medicine Centre (ECMC)
The Wellcome Trust

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 3829

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think